Compare ABVX & TPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ABVX | TPG |
|---|---|---|
| Founded | 2013 | 1992 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 8.9B |
| IPO Year | N/A | 2022 |
| Metric | ABVX | TPG |
|---|---|---|
| Price | $114.15 | $66.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $118.33 | $66.45 |
| AVG Volume (30 Days) | ★ 1.9M | 1.5M |
| Earning Date | 08-11-2025 | 02-10-2026 |
| Dividend Yield | N/A | ★ 2.64% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.10 |
| Revenue | $6,231,374.00 | ★ $4,255,344,000.00 |
| Revenue This Year | $6.80 | N/A |
| Revenue Next Year | N/A | $31.12 |
| P/E Ratio | ★ N/A | $676.74 |
| Revenue Growth | N/A | ★ 24.91 |
| 52 Week Low | $4.77 | $37.52 |
| 52 Week High | $148.83 | $70.38 |
| Indicator | ABVX | TPG |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 57.58 |
| Support Level | $116.20 | $63.79 |
| Resistance Level | $129.56 | $70.38 |
| Average True Range (ATR) | 7.87 | 1.63 |
| MACD | -2.47 | -0.11 |
| Stochastic Oscillator | 15.05 | 44.16 |
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
TPG Inc is an alternative asset management firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company focuses on large-scale, control-oriented private equity investments.